tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksMarket MoversTipRanks 50 IndexDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

LXRX Stock Latest News

Lexicon Pharmaceuticals Advances Study on Sotagliflozin for Hypertrophic Cardiomyopathy
Company AnnouncementsLexicon Pharmaceuticals Advances Study on Sotagliflozin for Hypertrophic Cardiomyopathy
4h ago
LXRX
Balanced Outlook for Lexicon Pharmaceuticals Amid Strategic Gains and Revenue Challenges
PremiumRatings
Balanced Outlook for Lexicon Pharmaceuticals Amid Strategic Gains and Revenue Challenges
10h ago
LXRX
Citi ups Lexicon target, opens ‘upside catalyst watch’
PremiumThe Fly
Citi ups Lexicon target, opens ‘upside catalyst watch’
1d ago
LXRX
Lexicon Pharmaceuticals Reports Strong Q2 2025 Results
PremiumCompany Announcements
Lexicon Pharmaceuticals Reports Strong Q2 2025 Results
2d ago
LXRX
Lexicon Pharmaceuticals Reports Strong Q2 2025 Earnings
PremiumCompany Announcements
Lexicon Pharmaceuticals Reports Strong Q2 2025 Earnings
2d ago
LXRX
Lexicon Pharmaceuticals: Strategic R&D Advancements and Strong Financial Performance Justify Buy Rating
PremiumRatingsLexicon Pharmaceuticals: Strategic R&D Advancements and Strong Financial Performance Justify Buy Rating
2d ago
LXRX
Lexicon reports Q2 EPS 1c, consensus (8c)
Premium
The Fly
Lexicon reports Q2 EPS 1c, consensus (8c)
2d ago
LXRX
LXRX Upcoming Earnings Report: What to Expect?
Premium
Pre-Earnings
LXRX Upcoming Earnings Report: What to Expect?
4d ago
LXRX
Lexicon regains compliance with Nasdaq minimum bid price requirement
PremiumThe Fly
Lexicon regains compliance with Nasdaq minimum bid price requirement
8d ago
LXRX
Lexicon Pharmaceuticals Regains Nasdaq Compliance
PremiumCompany Announcements
Lexicon Pharmaceuticals Regains Nasdaq Compliance
11d ago
8K
LXRX
Largest borrow rate increases among liquid names
PremiumThe Fly
Largest borrow rate increases among liquid names
17d ago
BMBL
BZAI
Lexicon Pharmaceuticals Granted Nasdaq Compliance Extension
PremiumCompany Announcements
Lexicon Pharmaceuticals Granted Nasdaq Compliance Extension
1M ago
8K
LXRX
Promising Outlook for Lexicon Pharmaceuticals’ Sotagliflozin in Type 1 Diabetes Management
PremiumRatingsPromising Outlook for Lexicon Pharmaceuticals’ Sotagliflozin in Type 1 Diabetes Management
2M ago
LXRX
Lexicon announces post-hoc analysis of clinical data on sotagliflozin
Premium
The Fly
Lexicon announces post-hoc analysis of clinical data on sotagliflozin
2M ago
LXRX
Lexicon Pharmaceuticals Holds Annual Stockholder Meeting
Premium
Company Announcements
Lexicon Pharmaceuticals Holds Annual Stockholder Meeting
2M ago
8K
LXRX
Lexicon Pharmaceuticals’ Sotagliflozin: Promising Phase 3 Developments Justify Buy Rating
PremiumRatings
Lexicon Pharmaceuticals’ Sotagliflozin: Promising Phase 3 Developments Justify Buy Rating
3M ago
LXRX
Lexicon announces details of SONATA-HCM study
PremiumThe Fly
Lexicon announces details of SONATA-HCM study
3M ago
LXRX
Lexicon Pharmaceuticals’ Earnings Call Highlights Strategic Gains
PremiumCompany Announcements
Lexicon Pharmaceuticals’ Earnings Call Highlights Strategic Gains
3M ago
LXRX
Lexicon Pharmaceuticals: Hold Rating Amid Strategic Restructuring and Clinical Uncertainties
PremiumRatings
Lexicon Pharmaceuticals: Hold Rating Amid Strategic Restructuring and Clinical Uncertainties
3M ago
LXRX
Lexicon Pharmaceuticals: Strong Financials and Promising R&D Pipeline Justify Buy Rating
PremiumRatingsLexicon Pharmaceuticals: Strong Financials and Promising R&D Pipeline Justify Buy Rating
3M ago
LXRX
Lexicon Pharmaceuticals Reports Promising Start to 2025
Premium
Company Announcements
Lexicon Pharmaceuticals Reports Promising Start to 2025
3M ago
LXRX
Lexicon reports Q1 EPS (7c), consensus (10c)
Premium
The Fly
Lexicon reports Q1 EPS (7c), consensus (10c)
3M ago
LXRX

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >